The IMID Forum

The Immune-Mediated Inflammatory Disease Forum
  • 0.0 (0)
  • EDUCATION
  • UPDATED FORTNIGHTLY

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

  1. Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile

    14 APR

    Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile

    Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘safety and clinical efficacy of bimekizumab in patients with active PsA who were bDMARD-naïve or TNFi-IR, and the second provided a comprehensive and updated overview of bimekizumab’s safety profile to support clinical decision-making.

    17 min
  2. Author Interview: Professor Helena Marzo-Ortega, March 2026

    9 APR

    Author Interview: Professor Helena Marzo-Ortega, March 2026

    Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Helena Marzo-Ortega an academic clinician and the Clinical Lead of the multi-award winning Leeds Specialist Spondyloarthropathy service at The Leeds Teaching Hospitals NHS Trust, as they discuss her recent paper ‘EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis’.

    38 min
  3. Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions

    26 MAR

    Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions

    Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.

    10 min
  4. Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers

    19 MAR

    Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers

    Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.

    33 min
  5. Author Interview: Doctor Carlo Tur, February 2026

    12 MAR

    Author Interview: Doctor Carlo Tur, February 2026

    Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Carlo Tur, from the department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University, Erlangen-Nurnberg., as they discuss his recent paper ‘Effects of different B-cell-depleting strategies on the lymphatic tissue’.

    30 min
  6. Author Interview - Professor Andrew Cope, 2026

    5 MAR

    Author Interview - Professor Andrew Cope, 2026

    Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.

    25 min
  7. Discussing RA: Pain outcomes and drug effectiveness of JAK inhibitors in RA and PsA

    27 FEB

    Discussing RA: Pain outcomes and drug effectiveness of JAK inhibitors in RA and PsA

    Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Taylor et al. where authors report the effects of UPA and ADA on pain in patients with active RA or PsA stratified by inflammatory status, and a paper by Sonomoto et al. which shows the effectiveness of TOF, BAR, UPA and FIL in patients with RA.

    9 min
  8. Discussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes

    13 FEB

    Discussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes

    Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.

    21 min
See All (397)

About

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

Information

  • Creator
    The Immune-Mediated Inflammatory Disease Forum
  • Years Active
    2024 - 2026
  • Episodes
    397
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    The IMID Forum

You Might Also Like